2009
DOI: 10.1111/j.1349-7006.2008.01004.x
|View full text |Cite
|
Sign up to set email alerts
|

DNA methyltransferase inhibitor 5‐aza‐CdR enhances the radiosensitivity of gastric cancer cells

Abstract: The National Comprehensive Cancer Network guidelines recommend radiotherapy as a standard treatment for patients with a high risk of recurrence in gastric cancer. Because radiation is harmful to the surrounding organs, a radiation sensitizer might therefore be useful to decrease the side effects of patients with advanced gastric carcinoma. The aim of the current study was to clarify the effect of a DNA methyltransferase inhibitor, 5-aza-2′-deoxycytidine (

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
65
0

Year Published

2010
2010
2024
2024

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 52 publications
(68 citation statements)
references
References 29 publications
3
65
0
Order By: Relevance
“…This unique characteristic has sparked enormous interest on the potential application of epigenetic drug, such as the Food and Drug administration-approved 5-aza-1 2′-deoxycytidine (5-aza-dC), 9 in gastric cancer patients. This notion is supported by multiple lines of in vitro evidence that 5-aza-dC can markedly increase the chemo-and radiosensitivity of different CpG island methylator phenotype gastric cancer cells, 5,10,11 and a recent in vivo study reporting the cancer chemopreventive effect of 5-aza-dC in gerbils infected with a stomach carcinogen Helicobacter pylori (H. pylori). 12 Nevertheless, the mechanistic actions of 5-aza-dC in gastric carcinogenesis remained incompletely understood, questioning the therapeutic value of epigenetic drug in this disease.…”
Section: Introductionmentioning
confidence: 87%
“…This unique characteristic has sparked enormous interest on the potential application of epigenetic drug, such as the Food and Drug administration-approved 5-aza-1 2′-deoxycytidine (5-aza-dC), 9 in gastric cancer patients. This notion is supported by multiple lines of in vitro evidence that 5-aza-dC can markedly increase the chemo-and radiosensitivity of different CpG island methylator phenotype gastric cancer cells, 5,10,11 and a recent in vivo study reporting the cancer chemopreventive effect of 5-aza-dC in gerbils infected with a stomach carcinogen Helicobacter pylori (H. pylori). 12 Nevertheless, the mechanistic actions of 5-aza-dC in gastric carcinogenesis remained incompletely understood, questioning the therapeutic value of epigenetic drug in this disease.…”
Section: Introductionmentioning
confidence: 87%
“…OCUM-2MLN (Fujihara et al, 1999) and OCUM-12 (Qiu et al, 2009) were derived from scirrhous gastric carcinomas. MKN-45 (Motoyama et al, 1986) and MKN-74 (Motoyama et al, 1986) were derived from non-scirrhous gastric carcinomas.…”
Section: Cell Linesmentioning
confidence: 99%
“…[9][10][11] However, there are a few reports on the radiosensitivity associated with exposure to DAC. [12][13][14][15] The present study, therefore, examined the effect of DAC on the radiation sensitivity of breast cancer cells.…”
Section: Introductionmentioning
confidence: 99%